Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

U.S. markets have been on a historic bull run since the end of the pandemic. However, many investors may start to be wary.

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash ...

The stock has been up 30% since Tuesday, and its market cap has now reached more than $1 trillion. SAVA: Cassava Sciences is ...

Today, Benzinga 's options scanner spotted 11 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

Bernardino covers the Healthcare sector, focusing on stocks such as Cassava Sciences, Novavax, and Can-Fite BioPharma. According to TipRanks, Bernardino has an average return of 5.7% and a 25.35% ...